Cookies

Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Business & Regulation Standards & Regulation, Business Practice, Small Molecules

High Fines for High Prices

Advanz Pharma has been fined over £100 million by the UK’s Competition and Markets Authority (CMA) for charging “excessive and unfair” prices for tablets used to treat thyroid hormone deficiency (1). From 2007 to 2017, the price of liothyronine tablets in Britain rose by more than 6,000 percent. Once the prices became unsustainable for the UK’s National Health Service (NHS), the medicine was added to a “drop list,” leaving many patients unable to access the treatment.

The CMA says that Advanz was able to sustain its progressive price inflation “because liothyronine tablets were among a number of drugs that, although genericised, faced limited or no competition and therefore could sustain repeated price increases… The price increases were not driven by any meaningful innovation or investment, volumes remained broadly stable, and the cost of producing the tablets did not increase significantly.”

In 2006, the NHS spent around £600,000 per year on the drug. By 2016, it was spending more than £30 million.

Advanz says it will appeal the decision.

Subscribe to The Medicine Maker Newsletters

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].

  1. Competition and Markets Authority (2021). Available at https://bit.ly/3rIXXTw.

About the Author

Stephanie Sutton

Making great scientific magazines isn’t just about delivering knowledge and high quality content; it’s also about packaging these in the right words to ensure that someone is truly inspired by a topic. My passion is ensuring that our authors’ expertise is presented as a seamless and enjoyable reading experience, whether in print, in digital or on social media. I’ve spent seven years writing and editing features for scientific and manufacturing publications, and in making this content engaging and accessible without sacrificing its scientific integrity. There is nothing better than a magazine with great content that feels great to read.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register